PanGenomic Health Announces Exclusive Distributorship Agreement with Colombian Subsidiary of Ayla Bioscience and Expiration of Non-Binding Letter of Intent

Vancouver, British Columbia, Canada, November 19, 2026 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA, FSE:LL3) announces that it is has signed an exclusive distributorship agreement (the "Distributorship Agreement") with Colombia-based Zeotech Group S.A.S. ("Zeotech"), a wholly-owned subsidiary of US-based Ayla Bioscience Inc.

Under the terms of the Distributorship Agreement, PanGenomic Health will have the right to market and sell a range of natural health products made by Zeotech from its production facility in Bogota, Colombia. The products include Zeofoodz, a line of high-nutrition functional foods, Zeophytoz, a line of high-quality botanical extracts and resins, and Zeomycel, a line of functional mushrooms. All products are made from natural ingredients sourced in the Andean and Amazon basins of South America, and dehydrated using Zeotech's patented technologies that avoid affecting molecular structure and biological activity.

PanGenomic Health will have an initial one year period of exclusivity in Canada to market and sell the Zeotech products, and the Company plans to market the private-labelled products online through its Agenta ecommerce platform and through natural health retail partners.

The Company further announced that it is no longer pursuing the proposed business combination transaction with Ayla Bioscience Inc., as previously announced on April 14, 2026. PanGenomic Health's non-binding Letter of Intent with Ayla Bioscience has expired in accordance with its terms. PanGenomic Health will continue to explore partnership opportunities to create a broad suite of products that provide consumers and health practitioners with access to personalized medicine tools and sustainable, high-value natural products.

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote alternative health solutions tailored to the health profile of each individual. To learn more about PanGenomic Health's products and services: www.pangenomic.com, www.agentahealth.store or email: info@pangenomic.com.

About Ayla Bioscience

Ayla Bioscience Inc. is a Delaware-based biomanufacturing company with operations in the United States and Colombia. The company's proprietary ZeoDry™ dehydration technology preserves bioactive integrity while improving yield efficiency and sustainability across a wide range of natural inputs. Ayla Bioscience develops and markets a portfolio of functional foods, nutraceuticals, and plant-derived bioactive products under its ZeoMycel™ and Zeophytoz™ brands. More information about Ayla Bioscience can be found at www.aylabioscience.com and zeodry.zeotech.com.co.

For more information, please contact:

Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 305 5369
fair@fairfax.partners

This news release includes certain statements that may be deemed "forward-looking statements", including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe", "plans" and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health's disclosure documents which can be found under PanGenomic Health's profile on www.sedarplus.ca. Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.